This is a preview of subscription content, log in via an institution to check access.
Notes
The study was sponsored by Merck, Sharp and Dohme (MSD) France.
Reference
Emery C, et al. Cost of Managing Type 2 Diabetes Before and After Initiating Dipeptidyl Peptidase 4 Inhibitor Treatment: A Longitudinal Study Using a French Public Health Insurance Database. Diabetes Therapy : Jan 2020. Available from: URL: http://doi.org/10.1007/s13300-020-00760-x
Rights and permissions
About this article
Cite this article
Dipeptidyl peptidase 4 inhibitors reduce costs in T2DM management. PharmacoEcon Outcomes News 846, 12 (2020). https://doi.org/10.1007/s40274-020-6551-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6551-9